We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

By LabMedica International staff writers
Posted on 15 Jul 2025

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. More...

Traditional methods for evaluating myeloma treatment often require large cell samples, complex preparation, and time-intensive measurements, making it challenging to monitor individual patient responses quickly and accurately. As treatment effectiveness can vary from patient to patient, it’s crucial to assess how cancer cells are responding to therapy in real-time. Now, researchers have developed a novel method to track cancer treatment responses in individual cells without the need for dyes or labels, providing faster and more precise insights into treatment effectiveness.

The mid-infrared optoacoustic microscopy (MiROM) technology, developed by researchers from Helmholtz Munich (Munich, Germany) and the Technical University of Munich (Munich, Germany), can track treatment responses in individual cancer cells without the need for dyes or labels. This technology uses mid-infrared light to detect molecular vibrations in proteins, which helps to identify structural changes such as protein misfolding, a key indicator of myeloma treatment response.

MiROM works by capturing ultrasound waves generated when proteins absorb infrared light, causing a localized temperature increase. This approach enables real-time visualization of protein changes inside living cells, allowing for more personalized treatment of multiple myeloma patients. The researchers demonstrated MiROM’s ability to analyze individual cells with minimal sample preparation, providing fast insights into how treatments impact protein structures at the cellular level.

The MiROM technology was tested and validated by applying it to living myeloma cells. It successfully detected protein misfolding and apoptosis, or programmed cell death, which are key indicators of whether cancer treatments are working or if drug resistance is developing. Published in Lancet Healthy Longevity, the findings suggest that MiROM can provide near-instantaneous assessments of cancer treatment effectiveness, paving the way for more personalized therapy adjustments.

Beyond myeloma, MiROM shows potential for diagnosing other diseases related to protein misfolding, such as Alzheimer’s and Parkinson’s. Future research will focus on optimizing the technology for faster imaging and enhancing its sensitivity for broader clinical applications, including drug screening, diagnostics, and home-based patient monitoring.

“We envision the use of MiROM in drug screening, diagnostic tests and home-based patient monitoring,” said Prof. Vasilis Ntziachristos, a senior investigator in the study.

Related Links:
Helmholtz Munich
Technical University of Munich


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A simple blood sample that allows DNA methylation could identify epigenetic biomarkers (Photo courtesy of 123RF)

Simple Blood Sample Could Identify Epigenetic Biomarkers to Predict CVD Risk in Type 2 Diabetes

People with type 2 diabetes face up to four times higher risk of cardiovascular events such as heart attacks, strokes, and angina compared to individuals without the condition. Yet, current tools used... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The new technology could predict who will benefit from immunotherapy (Photo courtesy of Max Delbrück Center)

New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response

A healthy immune system depends on complex communication between specialized cell types that detect, alert, and eliminate harmful threats. When these immune signaling pathways break down, the result can... Read more

Microbiology

view channel
Image: MycoMEIA Aspergillus Assay is the first FDA-cleared urine-based test for invasive aspergillosis (Photo courtesy of Pearl Diagnostics)

Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People

Invasive Aspergillosis (IA), a life-threatening fungal infection, poses a serious threat to immunocompromised individuals, especially those with hematologic malignancies, transplants, or severe lung diseases.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.